A Versatile Nanoplatform for Broad-Spectrum Immunotherapy by Reversing the Tumor Microenvironment

Area of Science:

• Biomedical Engineering
• Cancer Research
• Nanotechnology

Background:

• Immunotherapy is a key adjuvant for cancer treatment but faces challenges from tumor heterogeneity and low immunogenicity.
• Tumor acidosis and hypoxia limit the efficacy of current immunotherapies.

Purpose of the Study:

• To develop a nanoplatform (CP@mRBC-PpIX) to overcome tumor-associated immunosuppression.
• To enhance anti-tumor immune responses by targeting universal tumor features.

Main Methods:

• Constructed a nanoplatform (CP@mRBC-PpIX) that generates alkali and oxygen in response to tumor acidosis.
• Utilized CP@mRBC-PpIX to polarize tumor-associated macrophages towards an anti-tumor M1 phenotype.
• Employed photodynamic therapy with photosensitizers in the nanoplatform to increase tumor immunogenicity.

Main Results:

• The nanoplatform effectively reversed tumor acidosis and hypoxia.
• CP@mRBC-PpIX treatment polarized macrophages to M1 phenotype, enhancing the immune response.
• Photodynamic therapy converted "cold tumors" to "hot tumors," increasing T cell infiltration and response.
• The strategy demonstrated broad-spectrum immunotherapy, preventing tumor metastasis and recurrence.

Conclusions:

• The CP@mRBC-PpIX nanoplatform offers a promising strategy for broad-spectrum cancer immunotherapy.
• This approach effectively addresses tumor heterogeneity and enhances therapeutic outcomes by converting immunosuppressive tumors into immunogenic ones.